New Investigational Drug Shows Promise in Melanoma Treatment

The early phase I clinical study involved determining the role of the investigational drug MK-8353 in 26 patients with mutations in BRAF and RAS genes. This drug was developed to block cancer growth and resistance promoting signals such as ERK (Extracellular Signal-Regulated Kinase) in melanomas and other cancers resistant to treatment. New investigational compound MK-8353 shows promise in the treatment of advanced melanoma in early phase clinical trials.

Related Links